Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment

¹Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan;
²Division of Experimental Therapeutics, National Cancer Center, Kashiwa, Japan;
³Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan;
⁴Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan;
⁵Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan;
⁶Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan;
⁷Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan;
⁸Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, Fukuoka, Japan;
⁹Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, Japan;
¹⁰Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan;
¹¹Division of Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan;
¹²Department of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan;
¹³Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan;
¹⁴Clinical Oncology Division, Kochi Health Sciences Center, Kochi, Japan

Correspondence to: Toshikazu Moriwaki, MD, Ph.D., Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan. Tel/Fax: +81 298533218, e-mail: tmoriwak{at}gmail.com